Svastia enables the discovery and validation of novel biomarkers associated with cancer therapy response, through the collection of genetic and associated clinical data from hospitals.
Clinical trials: Improve patient selection and stratification in clinical trials through optimization of biomarkers and their thresholds
Cell/Animal Model Selection: Pre-clinical selection of cell or animal models requires optimal expression of markers (eg, drug targets or other proteins in the cancer pathways), to screen for the sensitivity of novel drug candidates. In addition to in vitro gene expression data of these models, it is important to ensure that the in vivo clinical data is in line with the expectations
Medical Devices: Validating biomarkers and their expression thresholds is key for medical device approval